Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. News about Lucid centers on its efforts to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, using its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
On this page, readers can follow Lucid’s announcements on business updates, financial results, capital-raising activities, and clinical data related to EsoGuard and EsoCheck. Company press releases have highlighted quarterly financial results, the number of EsoGuard tests processed, and revenues associated with those tests, reflecting the commercial adoption of its esophageal precancer detection tools.
Lucid’s news flow also includes developments in reimbursement and coverage, such as Medicare Local Coverage Determination (LCD) processes and Contractor Advisory Committee (CAC) meetings where medical experts have discussed coverage for EsoGuard. The company issues updates on these milestones because they are important for expanding patient access and insurance coverage for its tests.
In addition, Lucid regularly announces participation in investor and industry conferences, business update webcasts, and leadership appointments related to market access and government affairs. Clinical and real-world data updates, including large analyses of EsoGuard and EsoCheck performance in routine practice, are another key component of its news, providing insight into safety, tolerability, technical success, and use in at-risk GERD populations.
Investors and observers can use this news page to track Lucid’s progress as a commercial-stage diagnostics company focused on early detection of esophageal precancer, along with its financial disclosures and strategic communications.
Lucid Diagnostics Inc. (Nasdaq: LUCD) reported a substantial increase in EsoGuard test volume, achieving 60% growth quarter-over-quarter and over 300% year-over-year. The company’s CLIA-Certified LucidDx Labs is now fully operational and billing independently. Operating expenses for Q2 2022 were approximately $14.6 million resulting in a net loss of $14.6 million or $(0.41) per share. Despite no recognized revenue for the 850 tests processed, Lucid continues to expand its sales team and has initiated new Lucid Test Centers in key metropolitan areas.
Lucid Diagnostics has expanded its services by launching four new Lucid Test Centers in Orange County, Dallas-Fort Worth, Palm Beach County, and Columbus, Ohio. These centers will offer a non-invasive test to detect esophageal precancer in patients with chronic heartburn, utilizing the EsoGuard DNA Esophageal Test and EsoCheck device. With a projected opening of nine new centers this year, Lucid aims to enhance its national footprint and accessibility to early cancer detection. The company emphasizes that early detection can significantly reduce the risk of progressing to fatal esophageal cancer.
Lucid Diagnostics Inc. (NASDAQ: LUCD) announced significant updates to its esophageal precancer screening guidelines, as endorsed by the American Gastroenterological Association (AGA). These updates expand the target population for EsoGuard screening, now including at-risk patients without chronic heartburn symptoms. The update emphasizes non-invasive methods, highlighting EsoCheck as a viable alternative to traditional endoscopy. The AGA's endorsement comes amid rising esophageal cancer rates, furthering the need for accessible screening tools.
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) will hold a business update conference call on August 16, 2022, at 4:30 PM EDT. CEO Lishan Aklog will review company operations and growth strategies, while CFO Dennis McGrath will present the second-quarter financial results. The call can be accessed via phone or webcast through the company's website. PAVmed is a diversified medical technology company, with its subsidiary Lucid Diagnostics focusing on cancer prevention diagnostics with products like EsoGuard® and EsoCheck®.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has expanded its reach by entering into agreements with three preferred provider organizations (PPOs) and a specialized laboratory network. These agreements provide in-network access to Lucid's EsoGuard® DNA test, aimed at early detection of esophageal precancer, to millions of covered lives. The company emphasizes its goal of securing broad commercial reimbursement for EsoGuard testing, which is crucial for its growth strategy. This innovative test addresses a significant healthcare need, with esophageal cancer having a high mortality rate.
Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, will host a business update conference call on August 15, 2022, at 4:30 PM EDT. CEO Lishan Aklog will present the company's near-term milestones and growth strategy, while CFO Dennis McGrath will discuss Q2 2022 financial results. The call can be accessed via phone or webcast on Lucid's investor relations page. Lucid focuses on early detection of esophageal precancer in GERD patients, leveraging its EsoGuard® test and EsoCheck® device.
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announced that its CEO, Dr. Lishan Aklog, was recognized as one of the Most Influential Black Executives in Corporate America for 2022 by Savoy. This acknowledgment highlights his leadership and contributions in the medical technology sector, including advancements in diagnostics and digital health. Dr. Aklog expressed gratitude for the honor and emphasized his commitment to leveraging technology for patient care.
Lucid Diagnostics, a cancer prevention diagnostics company, announces that Dr. Lishan Aklog will present at the CG 42nd Annual Growth Conference from August 8-11 at the InterContinental Boston. His presentation is scheduled for August 11 from 12:30 pm to 12:55 pm ET. Additionally, Dr. Aklog will participate in 1x1 investor meetings at the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference on August 15-16. Lucid specializes in diagnostics for patients with GERD, using its EsoGuard and EsoCheck products for cancer prevention.
Summary not available.
PAVmed Inc. (PAVM, PAVMZ) provided a business update and preliminary financial results for Q1 2022, reporting a GAAP net loss of approximately $16.9 million or $(0.20) per share. EsoGuard related revenues reached $0.2 million, with a significant 76% increase from Q4 2021. Operating expenses totaled $19.3 million, including $4.8 million in stock-based compensation. The company maintains a strong balance sheet with $64.7 million in cash. Notably, ACG has endorsed nonendoscopic biomarker screening, benefiting Lucid's EsoGuard DNA Test. A conference call is scheduled today at 4:30 PM EDT.